Phase II evaluation of bryostatin-1 in metastatic melanoma - PubMed (original) (raw)
Clinical Trial
Phase II evaluation of bryostatin-1 in metastatic melanoma
A Y Bedikian et al. Melanoma Res. 2001 Apr.
Abstract
In this phase II study we assessed the efficacy of bryostatin-1 (NSC 339555) in metastatic melanoma patients when given intravenously either once a week at a dose of 25 microg/m2 per day over 24 h for 3 weeks or at 40 microg/m2 per day over 72 h every 2 weeks. Treatment courses were repeated every 4 weeks. Patients who had received one prior chemotherapy regimen for advanced melanoma, with or without biotherapy, were randomized to one or the other bryostatin-1 dose schedules until 12 patients were registered to each arm. Because there was one confirmed response among the 12 patients who received the 72 h dose schedule, 25 more patients were added to that arm. No prophylactic medications were given. Objective tumour measurements were used to assess the efficacy of the regimen. The National Cancer Institutes common toxicity criteria were used to grade reactions. In total, 49 patients with metastatic melanoma, none having symptomatic brain metastasis, were studied. Of these, 12 patients received the 24 h bryostatin-1 regimen, while the remaining 37 received the 72 h regimen. One patient receiving the 72 h regimen had a partial response lasting over 7 months. Muscle pain occurred in over 90% of the patients and was the dose-limiting side effect of the 72 h regimen. Grade 3/4 nausea and vomiting were more common on the 24 h regimen than on the 72 h one (35% versus 5% of patients). There was no therapy-related thrombocytopenia. Neutropenia was mild and mainly limited to patients receiving the 72 h regimen. Bryostatin-1 has limited activity against melanoma when given by 72 h intravenous infusion.
Similar articles
- A randomized phase II study of two schedules of bryostatin-1 (NSC339555) in patients with advanced malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group study.
Tozer RG, Burdette-Radoux S, Berlanger K, Davis ML, Lohmann RC, Rusthoven JR, Wainman N, Zee B, Seymour L; National Cancer Institute of Canada Clinical Trials Group. Tozer RG, et al. Invest New Drugs. 2002 Nov;20(4):407-12. doi: 10.1023/a:1020694425356. Invest New Drugs. 2002. PMID: 12448658 Clinical Trial. - Treatment of patients with metastatic melanoma with bryostatin-1--a phase II study.
Gonzalez R, Ebbinghaus S, Henthorn TK, Miller D, Kraft AS. Gonzalez R, et al. Melanoma Res. 1999 Dec;9(6):599-606. doi: 10.1097/00008390-199912000-00010. Melanoma Res. 1999. PMID: 10661772 Clinical Trial. - A phase II study of bryostatin 1 in metastatic malignant melanoma.
Propper DJ, Macaulay V, O'Byrne KJ, Braybrooke JP, Wilner SM, Ganesan TS, Talbot DC, Harris AL. Propper DJ, et al. Br J Cancer. 1998 Nov;78(10):1337-41. doi: 10.1038/bjc.1998.680. Br J Cancer. 1998. PMID: 9823975 Free PMC article. Clinical Trial. - Bryostatin-1: a novel PKC inhibitor in clinical development.
Kortmansky J, Schwartz GK. Kortmansky J, et al. Cancer Invest. 2003;21(6):924-36. doi: 10.1081/cnv-120025095. Cancer Invest. 2003. PMID: 14735696 Review. - The clinical development of the bryostatins.
Clamp A, Jayson GC. Clamp A, et al. Anticancer Drugs. 2002 Aug;13(7):673-83. doi: 10.1097/00001813-200208000-00001. Anticancer Drugs. 2002. PMID: 12187323 Review.
Cited by
- An Update on Protein Kinases as Therapeutic Targets-Part I: Protein Kinase C Activation and Its Role in Cancer and Cardiovascular Diseases.
Silnitsky S, Rubin SJS, Zerihun M, Qvit N. Silnitsky S, et al. Int J Mol Sci. 2023 Dec 18;24(24):17600. doi: 10.3390/ijms242417600. Int J Mol Sci. 2023. PMID: 38139428 Free PMC article. Review. - Activators and Inhibitors of Protein Kinase C (PKC): Their Applications in Clinical Trials.
Kawano T, Inokuchi J, Eto M, Murata M, Kang JH. Kawano T, et al. Pharmaceutics. 2021 Oct 20;13(11):1748. doi: 10.3390/pharmaceutics13111748. Pharmaceutics. 2021. PMID: 34834162 Free PMC article. Review. - Bryostatin Effects on Cognitive Function and PKCɛ in Alzheimer's Disease Phase IIa and Expanded Access Trials.
Nelson TJ, Sun MK, Lim C, Sen A, Khan T, Chirila FV, Alkon DL. Nelson TJ, et al. J Alzheimers Dis. 2017;58(2):521-535. doi: 10.3233/JAD-170161. J Alzheimers Dis. 2017. PMID: 28482641 Free PMC article. Clinical Trial. - Marine-derived angiogenesis inhibitors for cancer therapy.
Wang YQ, Miao ZH. Wang YQ, et al. Mar Drugs. 2013 Mar 15;11(3):903-33. doi: 10.3390/md11030903. Mar Drugs. 2013. PMID: 23502698 Free PMC article. Review. - Protein kinase C, an elusive therapeutic target?
Mochly-Rosen D, Das K, Grimes KV. Mochly-Rosen D, et al. Nat Rev Drug Discov. 2012 Dec;11(12):937-57. doi: 10.1038/nrd3871. Nat Rev Drug Discov. 2012. PMID: 23197040 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical